2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
European Heart Journal, 2020
Publication of this update to the 2016 guidelines follows emergence of a substantial body of evidence pertaining to low-density lipoprotein-C (LDL-C) reductions and risk of atherosclerotic cardiovascular disease (ASCVD). Monitoring LDL-C for longer periods is now required, with new goals for LDL-C reduction provided alongside important advice on patient management to enable clinicians to reduce CV risk through lipid modification. The guidelines also include recommendations for lipid management in patients with kidney disease, and guidance on frequency of lipid testing, HbA1c testing and blood glucose testing in patients at risk of ASCVD.
Read the full guidelines here, or use the following link, https://academic.oup.com/eurheartj/article/41/1/111/5556353.
© 2020 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. 10005969-01 10/20